NEW YORK (GenomeWeb News) – Molecular dermatology company PharmaGenoma said today that it has signed up Svenson Haar Studios to distribute its HairDx subsidiary’s genetic test to predict the likelihood of a common type of hair loss.

Svenson will distribute the HairDx test, which provides a gene-based analysis of the chances that men and women will develop androgenetic alopecia, through a network of 17 centers throughout Germany.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.